The case for & against
Bull & Bear analysis
Centene Corporation (NYSE: CNC) is a leading multi-national healthcare enterprise that focuses on government-sponsored healthcare programs, including Medicaid, Medicare, and services offered through the Health Insurance Marketplace. With a member base exceeding 28 million, Centene is positioned as a dominant player within the managed care sector, navigating regulatory complexities while providing high-quality healthcare solutions to underserved populations. The company's strategic emphasis on improving operational efficiencies and outcomes aligns with the broader trend of increasing demand for affordable healthcare solutions in the marketplace.
Bull says
- ↑Q1 adjusted EPS $3.37 topped consensus; raised full-year guide to >$3.40
- ↑Medicaid HBR 93.1% and 4.5% composite rate increase drive margin gains
- ↑Strong operating cash flow $4.4B and 0.7% dividend yield support returns
- ↑High book-to-price ratio and quality score indicate undervaluation
- ↑Positive momentum and analyst revisions factors signal growing consensus
- ↑Proactive state partnerships may secure contract renewals amid funding talks
Bear says
- ↓Earnings yield negative and weak profitability factors challenge margins
- ↓Medicaid membership expected to drop 5-6%, pressuring revenues
- ↓Regulatory uncertainty around work requirements and surprise billing risks funding
- ↓Rising behavioral health costs weigh on medical expense trends
- ↓Intense Medicaid/Medicare competition and APTC expirations threaten risk pools
- ↓Mixed analyst ratings and elevated short interest reflect investor skepticism
Investment themes with CNC
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- This morning, we reported first quarter adjusted diluted EPS of $3.37, exceeding our previous expectations for the period.
- The strength of our first quarter performance enables us to increase our full year 2026 adjusted EPS outlook to greater than $3.40, up from our previous expectation of greater than $3.
- We are pleased to be off to a strong start this year as increased visibility and operational improvements are yielding positive momentum and lifting our overall financial performance.
Bear points
- That said, we are beginning to see pockets of deceleration across this cohort, largely in line with our expectations for how trend would mature from 2025 into 2026.
- Though it is still early, we are pleased with the momentum we are seeing across the Medicaid portfolio, and we continue to see opportunity for advancement in 2026 and beyond.
- While trend continues to be elevated versus historical baselines, it is so far consistent with what we planned for in our bids, with slight favorability in Q1.